ReviewGut and liver2021
Recent Epidemiology of Nonalcoholic Fatty Liver Disease.
Review in Gut and liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- A systematic review and meta-analysis of efruxifermin's efficacy in improving liver fibrosis in patients with NASH/MASH.Frontiers in pharmacology · 2025Pooled it
- Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: a randomized placebo controlled clinical trial.BMC public health · 2024Trial
- Cola hispida Leaf Extract Attenuates Carbon Tetrachloride-Induced Hepato-Reno-Hematotoxicity via Antioxidant Modulation in Rats.Environmental toxicology · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.Gut and liver · 2026Review
- Consensus statement on obesity management in liver transplantation candidates.Updates in surgery · 2026Article
- Assessment of neck to height ratio as a predictive tool for metabolic dysfunction-associated steatotic liver disease in Korean adults: a cross-sectional analysis from the Korea National Health and Nutrition Examination Survey 2019-2021.Korean journal of family medicine · 2026Article
- Article
- Interleukin-38: A Candidate Biomarker for Disease Severity in Advanced Steatotic Liver Disease.Cells · 2026Article
- Dynamic Alterations of BMP9 in NAFLD: A Novel Hepatokine Marker of Metabolic Dysfunction and Disease Severity.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Global prevalence and predictors of depression and anxiety in patients with liver cirrhosis: a systematic review and meta-analysis.Frontiers in epidemiology · 2026Review
- Association between weight-adjusted waist index and hepatic steatosis and fibrosis: Analyses of the NHANES 2017 to 2020.Medicine · 2025Article
- Modern therapeutic approaches for hepatic tumors: progress, limitations, and future directions.Discover oncology · 2025Review
- Cultural and Molecular Factors Predisposed to Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.Nutrients · 2025Review
- Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023.Clinical and molecular hepatology · 2025Article
- Neutrophils in MASLD and MASH.BMB reports · 2025Review
- Exploring the Putative Involvement of MALAT1 in Mediating the Beneficial Effect of Exendin-4 on Oleic Acid-Induced Lipid Accumulation in HepG2 Cells.Biomedicines · 2025Article
- An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences.Molecular biology reports · 2025Review
- MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.Hepatology (Baltimore, Md.) · 2025Article
- Potential effects of Asian-adapted Mediterranean diet in depression and anxiety among women with metabolic dysfunction-associated steatotic liver disease: a secondary analysis.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing obesity epidemic and the increasing recognition of metabolic syndrome have contributed to the growing prevalence of nonalcoholic fatty liver disease (NAFLD), the most common form of liver disease worldwide. It is imperative to understand the incidence and prevalence of NAFLD as it is associated with a profound economic burden of hospitalizations, including the shifting trends in liver transplantation. The long-term cumulative healthcare cost of NAFLD patients has been shown to be 80% higher than that of non-NAFLD patients. We explore diagnostic challenges in identifying those with NAFLD who have a higher predilection to progress to end-stage liver disease. We aim to assess all-cause and cause-specific mortality as it relates to NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.